BSH 2020 Virtual Programme
Please see below BSH 2020 Virtual programme. There are a range of sessions taking place over the course of the five days, including plenary presentations, abstract sessions and SIG-led sessions around new findings. Delegates will be able to participate during the live sessions and ask their questions to the speakers. Content from BSH 2020 Virtual will be available for on demand viewing, for all registered participants, through to November 2021. CPD points are available.
| Time | Session | Track |
|---|---|---|
| 14:30 - 14:50 | Welcome from President Adele Fielding and Chair of the Programme Committee Tamara Everington | Plenary |
| 15:00 - 16:00 | Session in Partnership with by RCPath Malaria and other Anaemias in Tanzania Lucio Luzzatto Live Q&A from 15:40 - 16:00 |
Plenary |
| 16:15 - 17:15 | A snapshot of our digital landscape acceleration through COVID Rapidly upscaling digital support for clinical teams during COVID & beyond- Lisa Emery How do we get clinical information where & when we need it? Structured & coded or Intelligent Automation?- Phil Kenney Microsoft TEAMS – supporting clinical care now and into the future- Michael Nelson (Microsoft) Improvement through marginal gains – examples from clinical practice- Tamara Everington |
Scientific |
| 17:30 - 18:45 | BSH Guidelines Session Transfusion Presentations: Specification, Implementation and Management of Information Technology (IT) Systems in Hospital Transfusion Laboratories – Julie Staves Position paper on International Collaboration for Transfusion Medicine Guideline ‘Red blood cell specifications for patients with haemoglobinopathies: a systematic review and guideline – Sara Trompeter Live Q&A Transfusion Presentations - 18:00- 18:15 Haematology Oncology presentation: Diagnosis and Management of Chronic Myeloid Leukaemia- Graeme Smith Live Q&A Haematology Oncology presentation - 18:30 – 18:45 |
Scientific |
| Time | Session | Track |
|---|---|---|
| 08:00 - 09:30 | Sponsored Symposium Live Q&A from 09:00 - 09:30 |
Industry |
| 08:00 - 09:30 | Top abstracts with Expert Perspective in partnership with BJHaem/eJHaem: Nursing and
Education BSH20-OR-012 Transforming End of Life Care for Patients with Lymphoma – Understanding Training Needs within the Haematology Department of a Major Acute Teaching Hospital - Gehan Sooslpillai BSH20-OR-013 Simulating haematological emergencies: a pilot course for medical trainees - Luci Chen BSH20-OR-015 The haemato-oncology patient experience of the process of palliative care in the last year of life: A Constructivist grounded theory study - Karen Campbell BSH20-OR-016 The Role Of A Multiple Myeloma Patient Support Programme In Patient Management – Interim Data, December 2019 - Lisa Ferguson |
Abstract |
| 10:30 - 11:50 | Top abstracts with Expert Perspective in partnership with BJHaem/eJHaem: Acute Leukaemia and
Transplant BSH20-OR-001 Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14 - Anthony Moorman BSH20-OR-002 The FLAMSA-Bu conditioning regimen does not improve outcome in patients allografted for high risk acute myeloid leukemia and myelodysplasia irrespective of pre-transplant MRD: results of the UK NCRI FIGARO trial - Charles Craddock BSH20-OR-004 First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006) - Adele Fielding |
Abstract |
| 10:30 - 12:00 | Nursing Session Cytokine Release Syndrome – from a Clinical Trial perspective – Gavin Cooper & Leigh Wood Improving understanding and access to clinical trials through the development of a nurse-led Clinical Trials Support Service- Helen McNaught Palliative Care - Case study discussion Haematology health professionals survey- Orla McCourt Live Q&A from 11:50 (Sarah Jordan, Jackie Green, Karen Stanley, Rebecca Hallam and Gavin Cooper) |
Scientific |
| 12:30 - 13:30 | Poster Walk | Abstract |
| 16:00 - 17:30 | Sponsored Symposium Live Q&A from 17:00 - 17:30 |
Industry |
| 16:00 - 17:30 | Sponsored Symposium Live Q&A from 17:00 - 17:30 |
Industry |
| 18:00 - 19:00 | Malignant Haematology Diagnostics: How is genomics progressing? Shirley Henderson, Polly Talley, and Angela Hamblin Live Q&A from 18:45 - 19:00 |
Scientific |
| 18:00 - 19:00 | Paediatric SIG - Impacts of COVID-19 Impact of COVID on children undergoing chemotherapy – Ashley Gamble Impact of COVID on children with haemoglobinopathy- Mark Layton Live Q&A from 18:30 |
Scientific |
| Time | Session | Track |
|---|---|---|
| 08:00 - 09:00 | EHA/BSH Session - presentation relating to COVID-19 Evolution in the place of diagnostics in lymphoid malignancies: Tales from MRD - Elizabeth Macintyre Live Q&A from 08:20 Monitoring acute leukaemia using multiparameter flow cytometry: the UCLH experience - Rajeev Gupta Live Q&A from 08:50 - 09:00 |
Plenary |
| 09:15 - 10:00 | BSH Awards BSH NIHR Awards Lifetime Achievement Awards |
Plenary |
| 10:30 - 12:00 | Top abstracts with Expert Perspective in partnership with BJHaem/eJHaem:
Lymphoma/CLL BSH20-OR-023 ELEVATE-TN: A phase 3, multi-centre, open-label study of Acalabrutinib (Ab) combined with Obinutuzumab (O) or Ab alone vs O Plus Chlorambucil (Clb) in patients (pts) with Treatment-Naive Chronic Lymphocytic Leukemia (TN-CLL) - Talha Munir BSH20-OR-024 KTE-X19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results from Phase 2 of ZUMA-2 - Michael Wang BSH20-OR-025 Five years on: a real-world observational study of patients receiving ibrutinib for relapsed / refractory MCL from the UK and Ireland. - David Tucker BSH20-OR-026 A 10-Year Analysis of Outcomes for Advanced-Stage Hodgkin Lymphoma Comparing Extended Follow-up of the Multinational RATHL Trial with Real-World Patients Treated with ABVD or Escalated BEACOPP in the East of England - James Russell BSH20-OR-027 Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in the UK - Andrea Kuhnl BSH20-OR-028 Sequential MATRIX-RICE Therapy Followed by Autologous Stem Cell Transplant In Patients with Diffuse Large B-cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial - Kate Cwynarski |
Abstracts |
| 10:30 - 12:00 | Top abstracts with Expert Perspective in partnership with BJHaem/eJHaem: Transfusion and Red
Cells BSH20-OR-029 Resolution of sickle cell disease manifestations in patients treated with LentiGlobin gene therapy: updated results from the phase 1/2 HGB-206 Group C study - Alexis Thompson BSH20-OR-030 Intravenous Morphine Achieved a More Sustained Pain Response during Acute Pain Crisis in Adult Sickle Cell Disease Patients Compared to Intramuscular Pethidine - Marian Opoku-Agyakwa BSH20-OR-031 UK Results from the International Sickle Cell World Assessment Survey (SWAY): Patients with Sickle Cell Disease (SCD) Experience Work Impairment and Decreased Productivity - Baba Inusa BSH20-OR-032 Cold Stored Platelets Reverse Thrombocytopathy following Cardiac Surgery - Thomas Scorer BSH20-OR-033 Results for the REAL pilot randomised trial of red cell transfusion in acute myeloid leukaemia: is there sufficient evidence of equipoise to support a definitive study? - Suzy Morton |
Abstracts |
| 12:30 - 13:30 | Poster Walk | Abstracts |
| 12:30 - 14:00 | Sponsored Symposium Live Q&A from 13:30 - 14:00 |
Industry |
| 16:00 - 17:45 | The Crucible - What lessons learnt during the COVID-19 pandemic should change future
practice in haematology? The elephant in the room: escalation of care and DNACPR - Kate Rogers & Naomi Dean Clinical Trials during COVID-19 – Embracing the Move Towards Patient-Centric Clinical Research - Marquita Camilleri Home transfusion service may change future practice in haematology - Abdul Adamu A hospital avoidance strategy should be forefront in our minds - Joshua Bomsztyk The COVID-19 pandemic: An unintentional opportunity to evaluate whether less is more - Wei Yee Chan |
Scientific |
| 18:00 - 19:00 | NCEPOD report on care of patients with Acute PE Vivek Srivastava Live Q&A from 18:40 - 19:00 |
Scientific |
| 18:00 - 19:00 | Haemostasis and Thrombosis Task Force – Hot Topics in Coagulation with a focus on
COVID-19 Reversal of Direct Oral Anticoagulants - Marc Samama (Live Q&A from 18:10 - 18:15) What does the Radiology tell us about the vasculopathy of COVID-19 lung disease?- Graham Lloyd-Jones (Live Q&A 18:25 - 18:30) Debate: Should the dose or duration of anticoagulants for VTE prevention be increased in patients with COVID-19 while we are awaiting the results of clinical trials?- Keith Gomez - Introduction Charlotte Bradbury - will argue that these non-standard doses of anticoagulation should be restricted to clinical trials Mike Laffan - will argue for their use in routine clinical care. (Live Q&A 18:50 - 19:00) |
Scientific |
| Time | Session | Track |
|---|---|---|
| 08:00 - 09:30 | Sponsored Symposium Live Q&A 09:00 - 09:30 |
Industry |
| 10:30 - 12:00 | Top abstracts with Expert Perspective in partnership with BJHaem/eJHaem:
Paediatrics BSH20-OR-035 Post-transplant Outcomes of Children With Primary Hemophagocytic Lymphohistiocytosis Given Emapalumab to Control Disease - Anupama Rao BSH20-OR-036 The Long-Term Quality of Life Impact of Vincristine Neurotoxicity in Paediatric Acute Lymphoblastic Leukaemia Survivors- A Retrospective Cohort Study - Claire Hogan BSH20-OR-037 Clinical outcomes following autologous haematopoietic stem cell transplantation with LentiGlobin gene therapy in the phase 3 Northstar-2 and Northstar-3 studies for transfusion-dependent β-thalassemia - John Porter BSH20-OR-038 Analysis of Second Line Treatments for Children with Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in the UK. - Bobby Chaudhury BSH20-OR-039 Updated Results From the Single-Arm, Open-label, Long-term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP) - John Grainger |
Abstracts |
| 10:30 - 12:00 | Top abstracts with Expert Perspective in partnership with BJHaem/eJHaem: Thrombosis and
Haemostasis BSH20-OR-040 A novel assay of Neutrophil Extracellular Traps (NETs) formation independently predicts DIC and identifies the rationale for anti-IL-8 therapies - Simon Abrams BSH20-OR-042 Gain of function variant of prothrombin (p.R541W) causes dominant heritable thrombosis and is associated with antithrombin resistance. - Suthesh Sivapalaratnam BSH20-OR-043 When is Immune Thrombocytopenia not Immune Thrombocytopenia? Using high throughput sequencing to distinguish patients with inherited thrombocytopenia and diseases of immune dysregulation. - Nehal Joshi BSH20-OR-044 Molecular dynamics analysis provides mechanistic insights into ACTN1-related thrombocytopenia - Sarah Westbury BSH20-OR-045 Factor VIII Use In The Treatment Of Breakthrough Bleeds In Persons With Haemophilia A Without Inhibitors On Emicizumab Prophylaxis: The Phase III HAVEN 3 Study Experience - Michael Callaghan |
Abstracts |
| 12:30 - 13:30 | Poster Walk | Abstracts |
| 12:30 - 14:00 | Sponsored Symposium Live Q&A from 13:30 - 14:00 |
Industry |
| 16:00 - 17:30 | Sponsored Symposium Live Q&A from 17:00 - 17:30 |
Industry |
| 16:00 - 17:30 | Sponsored Symposium Live Q&A from 17:00 - 17:30 |
Industry |
| 18:00 - 19:20 | BSH/ASH Keynote Speaker presentation relating to COVID-19 UK's COVID Response - Steve Powis The Effects of COVID-19 on Hematology: US and ASH Perspectives - Stephanie Lee Live Q&A from 18:55 |
Plenary |
| Time | Session | Track |
|---|---|---|
| 08:00 - 09:00 | Obstetric Haematology SIG - Impacts of COVID-19 Thrombophilia in Pregnancy - Saskia Middeldorp Risk Assessment for Venous Thrombosis in Pregnancy - Rachel Rayment Live Q&A from 08:50 - 09:00 |
Scientific |
| 09:15 - 10:15 | General Haematology Task Force - Impacts of COVID-19 Pandemic Introduction - Dr Mamta Garg Care of haematology patients during COVID-19 pandemic - Dr John Willan B12 replacement during COVID-19 pandemic - Dr Mamta Garg Management of ITP during the Covid-19 pandemic - Dr Sue Pavord Shielding advice for hyposplenic patients - Quentin Hill Live Q&A from 09:55 |
Scientific |
| 10:30 - 12:00 | Top abstracts with Expert Perspective in partnership with BJHaem/eJHaem: General
Haematology BSH20-OR-006 CIP2A: its validation as a predictive biomarker of subsequent progression to blast crisis in CML. - Claire Lucas BSH20-OR-007 Efficacy of Bosutinib in Imatinib-Resistant vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results From the Phase 4 BYOND Study - Gianantonio Rosti BSH20-OR-008 Decision Tree Application (DTA) to Support Accurate Diagnosis of Myeloid Malignancies - Thomas Coats BSH20-OR-009 Splenectomy in immune thrombocytopenia: do changing treatment patterns for ITP affect outcome? Data from the UK ITP registry - Sophie Todd BSH20-OR-010 Fostamatinib as Second-Line Therapy and in Earlier Stage Disease in Patients with Immune Thrombocytopenia - Nichola Cooper BSH20-OR-011 A Phase 2 Open-label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Haemoglobinuria Who Have an Inadequate Response to Eculizumab Monotherapy - Austin Kulasekaraj |
Abstract |
| 11:00 - 12:00 | Top abstracts with Expert Perspective in partnership with BJHaem/eJHaem: Myeloma BSH20-OR-019 Tailoring treatment for patients with newly diagnosed high-risk myeloma – feasibility results of the UKMRA OPTIMUM (MUKnine) trial - Matthew Jenner BSH20-OR-021 Pomalidomide, Bortezomib, and Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: a Subanalysis of the OPTIMISMM Phase 3 Trial - Jindriska Lindsay BSH20-OR-022 Ixazomib-dexamethasone versus physician’s choice in patients with relapsed/refractory systemic AL amyloidosis: primary data from the phase 3 TOURMALINE-AL1 trial - Ashtosh Wechalekar |
Abstract |
| 12:30 - 13:30 | Managing Myeloma in the era of COVID-19 - Ceri Bygrave Live Q&A from 13:10 - 13:30 |
Scientific |
| 12:30 - 13:30 | Global Haematology SIG Group - Impacts of COVID-19 COVID in Caribbean and challenges to the blood supply- Kenneth Charles Covid-19 in Bangladesh- Challenges in Blood Transfusion Management and Thalassaemic Patient Care– Tashmim Farhana Dipta COVID and blood supplies in Ghana maintaining donor motivation and blood supplies – Lucy Asamoah-Akuoko Live Q&A from 13:15 - 13:30 |
Scientific |
| 16:00 - 17:30 | Sponsored Symposium Live Q&A from 17:00 - 17:30 |
Industry |
| 18:00 - 18:30 | Take home/Stay at home messages | Scientific |
| 18:30 - 19:00 | Summary and Key Learnings of the BSH 2020 Virtual | Scientific |
ON DEMAND LIBRARY
The BSH 2020 Virtual on demand library contains a various range of resources, from educational to anniversary videos, and they can be accessed at any time.
BSH LYMPHOMA SIG ONLINE MEETING – DILEMMAS IN MDT
Controversies in the use of radiotherapy in lymphoma
Professor Tim Illidge and Dr Cathy Burton
CNS prophylaxis in DLBCL
Dr Pam McKay and Dr Sunil Iyengar
How should we treat early stage and high-risk DLBCL?
Dr Christopher Fox and Professor Andrew Davies
MDT dilemmas in CAR-T therapy
Dr Andrea Kuhnl and Dr Kate Cwynarski
How should we treat older Hodgkin lymphoma?
Dr Wendy Osborne and Dr Graham Collins
Immune suppression LPD
Dr Sridar Chaganti and Dr Fiona Miall
Challenges and controversies in management of MCL in 2020
Dr Toby Eyre and Professor Simon Rule
Biology-based lymphoma treatment
Dr Daniel Hodson and Dr Jessica Okosun
Low-grade lymphoma
Dr Kim Linton and Dr Beth Phillips
BSH 60th ANNIVERSARY - AN EXCLUSIVE PREVIEW FOR BSH VIRTUAL PARTICIPANTS
The first meeting of BSH took place in London on 19 November 1960. For 60 years BSH has been dedicated to helping members support people with blood disorders and diseases. We are planning to use our 60th anniversary as an opportunity to recognise the tremendous contribution haematology professionals have made to advancing the specialty and transforming patient care.
Enjoy an exclusive preview of the following anniversary content:
- BSH 60th Anniversary Address - Professor Adele Fielding, BSH President
- An interview with Professor Victor Hoffbrand (BSH President from 1989-90), led by Suthesh Sivapalaratnam